Political Quotes

“I would also refer my colleagues to the following news articles: ``Trump's HHS Nominee Got A Sweetheart Deal from A Foreign Biotech Firm,'' a story published by Kaiser Health News on January 13, 2017; ``Representative Tom Price Got Privileged, Discounted Offer on Biomedical Stock, Company Says,'' a story published by the Wall Street Journal on January 30, 2017; and ``In accidental `reply all' to reporter, Collins thanks CEO for defending HHS nominee,'' a story published by CNN on January 31, 2017. Mr. President, I wish to now discuss what is known about the facts and timing of Congressman Price's investment in Innate. This is a timeline that is based on public documents, press reports, and information the nominee provided the Finance Committee. If you have never heard of Innate until the last few weeks, you would be forgiven. The New York Times described it as a ``tiny pharmaceutical company from Australia that has no approved drugs and no backing from flashy venture capital firms.'' Innate has fewer than a dozen full-time employees. The company's stock was first listed on the Australian Stock Exchange in 2013, and until recently its market capitalization was well below $100 million. Innate has never generated revenue from drug sales. It has repeatedly teetered on the brink of running out of cash. It has just 2,500 shareholders. By way of comparison, a major American pharmaceutical company could have hundreds of thousands of shareholders.…”